Refine by
Joint Disease Articles & Analysis
15 news found
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. ...
ByOncoVITA
The company is also co-developing new drugs with Mayo Clinic in key disease areas, including oncology, hematology, bone/joint disorders, and neurological diseases. ...
The CUVIS-Joint robotic platform is currently being used by surgeons in Korea and India with great success. ...
The core technology of the TSolution One has been used in thousands of successful total joint replacements worldwide. THINK Surgical actively collaborates with healthcare professionals around the globe to refine our orthopedic products, improving the lives of those suffering from advanced joint disease with precise, accurate, and intelligent ...
The core technology of the TSolution One has been used in thousands of successful total joint replacements worldwide. THINK Surgical actively collaborates with healthcare professionals around the globe to refine our orthopedic products, improving the lives of those suffering from advanced joint disease with precise, accurate, and intelligent ...
VeriSIM will engage Mayo Clinic physician researchers in key disease areas including oncology, hematology, bone/joint-disorders, and neurological diseases. ...
Dry Eye Syndrome is a chronic disease that affects the productivity and quality of life of 1.52 billion people worldwide [1]. The COVID-19 pandemic has further exacerbated the problem, as prolonged time in front of screens is a risk factor for the disease. Other risk factors include aging, eye surgeries, dry environments, long-term wearing of contact lenses, ...
The core technology of the TSolution One has been used in thousands of successful total joint replacements worldwide. THINK Surgical actively collaborates with healthcare professionals around the globe to refine our orthopedic products, improving the lives of those suffering from advanced joint disease with precise, accurate, and intelligent ...
“Given his track record of success over decades with Stryker Corporation, including his time as president of the Joint Replacement Division and his experience with Mako robotic-arm technology, Stuart Simpson is uniquely qualified to lead THINK. ...
In sports alone, knee injuries account for 41% of all injuries, and rapidly increasing in prevalence is knee osteoarthritis, a disabling joint disease. The KneeKGTM goes beyond the current standard of care by providing clinicians with real-time, quantifiable data that objectively and accurately assess dynamic knee function to prevent or rehab knee pain and ...
ByEmovi
Innovation Center project of Merck collaborates to develop smart neuro-modulation for targeted treatment of chronic diseases. Joint development agreement represents a promising step towards a highly selective and efficient next generation of bioelectronic therapies powered by graphene. ...
About Osteoarthritis Osteoarthritis is the most common chronic degenerative joint disease, characterized by progressive wear of joint cartilage. Clinical manifestations of OA in the knee include, but are not limited to, pain in and around the joint and limited joint motion. Due to the inability of ...
OA is a painful, chronic and progressive joint disease that affects more than 100 million people globally. Symptomatic OA afflicts more than 30 million Americans, and loss of joint function as a result of this condition is a major cause of work disability and reduced quality of life. ...
Orthocell Ltd (ASX: OCC) is today celebrating the lifelong achievements of Professor Lars Lidgren, a Swedish surgeon, researcher, entrepreneur and Orthocell board member, who has been awarded an honorary fellowship by the American College of Surgeons (ACS). Orthocell Managing Director, Paul Anderson, said the fellowship recognises significant milestones in Professor Lidgren’s career, ...
This new distribution arrangement will get 14-3-3η testing into the hands of more investigators worldwide, including key opinion leaders and pharmaceutical companies, to advance and grow the body of data for this novel joint damage biomarker in autoimmune diseases. There is increasing international momentum to investigate the role of 14-3-3η in various ...